Navigation Links
Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
Date:6/1/2009

Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Osteoporosis finds that concerns about the long-term safety of bisphosphonates -- which currently dominate the market -- will help convince primary care physicians and specialists to switch patients to PTH analogues and novel agents such as denosumab. The uptake of denosumab, which has a convenient dosage regimen of bi-annual subcutaneous injections, will drive the agent to achieve blockbuster sales of $2 billion in 2018 for the treatment of osteoporosis and osteopenia. The report also forecasts that Forteo/Forsteo will achieve blockbuster status in 2018 with sales of approximately $2 billion. Forteo/Forsteo's uptake will be achieved as a result of its efficacy in reducing the frequency of fractures as well as the prevalent safety concerns about the bisphosphonates.

The report also finds that that the launches of third-generation selective estrogen receptor modulators (SERMs), most notably Eli Lilly's arzoxifene, will drive market growth. Physicians will increasingly prescribe these agents, particularly if they demonstrate significant efficacy in reducing nonvertebral fractures.

"Interviewed experts indicate that arzoxifene is the most promising of the third-generation SERMs, as they believe it may be as efficacious as Pfizer's Fablyn without increasing mortality," said Decision Resources Analyst Jeremy Goldman, M.D. "If Phase III clinical trial data confirms this, we forecast that arzoxifene will become the market-leading SERM, generating sales of $600 million in 2018."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Virus Could Help Drive Obesity
2. Back to School Means Return of School Blood Drives
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
5. Customized virus kills brain tumor stem cells that drive lethal cancer
6. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
7. Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
8. Brain Defect Helps Drive Fragile X Syndrome
9. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
10. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
11. Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... Thomas Vas-Don suffered from severe injury due to an ... successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” (published by ... massage, anatomy , trigger points and referral pain patterns . , In ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell ... years. The technology is so cutting edge, in fact, the U.S. Food and ... cell procedures. However, successful patient outcomes in certain clinical stem cell procedures have ...
(Date:2/22/2017)... CRANBURY, N.J. (PRWEB) , ... February 22, 2017 ... ... than a one-size-fits-all approach, leads to fewer trips the emergency room, fewer hospital ... in The American Journal of Managed Care® (AJMC®) finds. The study can be ...
(Date:2/22/2017)... ... ... Sideline Products participated in the World Horse Expo held in Timonium, MD ... production crew. Tom Seay’s program “Best of America by Horseback” is broadcasted on ... be featured on April 6, 2017. After the broadcast, the clip will be posted ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Centers ... to help small practices in Delaware, New Jersey, Pennsylvania and West Virginia prepare ... Access and CHIP Reauthorization Act of 2015 (MACRA). , This technical assistance, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
(Date:2/23/2017)... England and DEERFIELD, Ill. ... U.S.A. , Inc., a wholly-owned subsidiary of ... a joint venture between Cambridge Cognition Holdings PLC and ... use of a specially designed app on an Apple ... patients with Major Depressive Disorder (MDD). Depression ...
(Date:2/22/2017)... Feb. 22, 2017 General Report Contents ... Value & Growth Trends - Market Drivers & ... for each chapter segment - Section on recent ... report: https://www.reportbuyer.com/product/4665946/ This market ... methods: articulated arm lasers, fiber-delivered lasers and direct ...
Breaking Medicine Technology: